柔木丹颗粒治疗乙型肝炎肝纤维化随机对照研究

发布时间：2019-08-04 11:42

【摘要】：目的探讨柔木丹颗粒治疗乙型肝炎肝纤维化的临床疗效。方法将67例乙型肝炎肝纤维化患者随机分为2组,治疗组37例应用柔木丹颗粒治疗,对照组30例采用大黄蛰虫丸治疗,3个月为1个疗程,总疗程为1年,观察2组肝功能指标、血清肝纤维化指标、APRI及门静脉和脾静脉宽度变化情况。结果疗程结束后,治疗组总有效率为75.7%,对照组为66.7%,2组疗效相当(P0.05);2组治疗后肝功能指标、APRI、血清肝纤维化指标以及症状评分均明显改善(P均0.05),且治疗组症状评分(右胁部疼痛不适、肢体乏力、症状总积分)、APRI、HA改善情况均明显优于对照组(P均0.05)。结论柔木丹颗粒治疗乙型肝炎肝纤维化与大黄蛰虫丸疗效相当,值得临床推广。
[Abstract]:Objective to investigate the clinical effect of Ruomudan granule in the treatment of hepatitis B liver fibrosis. Methods 67 patients with hepatitis B hepatic fibrosis were randomly divided into two groups. 37 patients in the treatment group were treated with Ruomudan granule, and 30 patients in the control group were treated with rhubarb Zhengshi Pill for 3 months as a course of treatment for 1 year. The changes of liver function index, serum hepatic fibrosis index, APRI, portal vein and spleen vein width were observed in the two groups. Results at the end of the course of treatment, the total effective rate was 75.7% in the treatment group and 66.7% in the control group. After treatment, the indexes of liver function, serum hepatic fibrosis index and symptom score of APRI, in the two groups were significantly improved, and the improvement of APRI,HA in the treatment group was significantly better than that in the control group (P < 0.05), and the improvement of APRI,HA in the treatment group was significantly better than that in the control group (P < 0.05). Conclusion the therapeutic effect of Ruomudan granule on hepatitis B liver fibrosis is the same as that of rhubarb Zhengshi Pill, which is worth popularizing in clinic.
【作者单位】：陕西中医药大学附属医院;
【基金】：陕西中医药大学青年基金项目(2015QN13)
【分类号】：R512.62;R575

【相似文献】